Two research peptides popular for recovery. Both are largely backed by preclinical (animal) data, both are not FDA-approved, and both are prohibited in sport.
BPC-157 and TB-500 are frequently discussed together for tissue repair. They differ in origin and proposed mechanism, but share the same honest caveat: the evidence is mostly preclinical, neither is FDA-approved, and both are on the WADA Prohibited List.
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Synthetic 15-amino-acid peptide from a gastric protein sequence | Synthetic fragment based on Thymosin Beta-4 |
| Proposed mechanism | Angiogenesis, NO modulation, fibroblast effects | Actin regulation, cell migration, angiogenesis |
| Evidence strength | Predominantly preclinical; limited human data | Predominantly preclinical; limited human data |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Sport (WADA) | Prohibited | Prohibited |
Neither is an established human treatment. Both are research compounds with real product-quality and safety unknowns. If you're weighing them, that conversation belongs with a licensed provider who can discuss the (limited) evidence, legality, and sourcing.
If you'd like help applying this information to your own health, schedule a consultation with the Bearing team.
Request a Consultation